| Particulars (Rupees in Crores.) | Sept-2025 | Mar-2025 | Sept-2024 | Mar-2024 | Sept-2023 |
|---|---|---|---|---|---|
Gross Sales | 366.45 | 454.82 | 467.1 | 437.69 | 381.68 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 366.45 | 454.82 | 467.1 | 437.69 | 381.68 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 22.22 | 12.39 | 15.09 | 20.62 | 10.24 |
Total Income | 388.68 | 467.21 | 482.19 | 458.31 | 391.92 |
Total Expenditure | 353.75 | 400.48 | 404.27 | 372.48 | 336.22 |
PBIDT | 34.92 | 66.73 | 77.92 | 85.84 | 55.7 |
Interest | 6.99 | 7.71 | 6.83 | 7 | 9.35 |
PBDT | 27.93 | 59.02 | 71.09 | 78.84 | 46.35 |
Depreciation | 17.56 | 17.48 | 17.07 | 17.69 | 15.55 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 0 | 0.06 | -0.15 | 0.11 | 0 |
Deferred Tax | -0.15 | -0.1 | 0 | -3.23 | 0 |
Reported Profit After Tax | 10.52 | 41.58 | 54.17 | 64.27 | 30.8 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 9.34 | 43.07 | 56.59 | 62.96 | 29.21 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 9.34 | 43.07 | 56.59 | 62.96 | 29.21 |
EPS (Unit Curr.) | 1.84 | 8.49 | 11.16 | 12.41 | 6.35 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 50.72 | 50.72 | 50.72 | 50.72 | 50.72 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 9.52 | 14.67 | 16.68 | 19.61 | 14.59 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 2.87 | 9.14 | 11.59 | 14.68 | 8.06 |
At around 12.53 PM, Orchid Pharma was trading 5% higher at ₹740.40, against the previous close of ₹705.15 on NSE.
The inspection raised, seven minor observations none related to data integrity, and therefore, the facility remains compliant under stringent regulatory standards.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.